BDC
LIVE

Serial Number

79392996

Owner

Bicycletx Limited

Attorney

Christina M. Licursi

Filing Date

Dec 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BDC Trademark

Serial Number: 79392996 • Registration: 7741579

BDC is a trademark filed by Bicycletx Limited on December 19, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Bicycletx Limited (33 trademarks)

Blocks A & B Portway Building,

Entity Type: 99

Trademark Details

Filing Date

December 19, 2023

Registration Date

April 1, 2025

Published for Opposition

February 11, 2025

Goods & Services

Scientific and technological services and research and design relating thereto, namely, scientific research and new product design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; medical research services, namely, industrial analysis and research services in the field of medicine; research and development services in the field of pharmaceutical preparations; medical research services; pharmaceutical research services, namely, pharmaceutical testing and clinical trials; scientific research in the nature of conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; scientific research consulting, namely, providing information consultancy and advisory services relating to the aforesaid in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents

Pharmaceutical preparations for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the treatment of cancer; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical preparations for use in preventing and treating infections; pharmaceutical products and preparations for the treatment of respiratory disease; pharmaceutical preparations for the treatment and prevention of cardiovascular disease; pharmaceutical preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical preparations for use in medical diagnostics and imaging; pharmaceutical preparations for the treatment and prevention of renal disease; pharmaceutical preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical preparations for the treatment and prevention of muscular skeletal disease

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 31, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 14, 2025 FICS
FINAL DISPOSITION PROCESSED
Oct 14, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 19, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 3, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 2, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 1, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 1, 2025 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 26, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 26, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 26, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 26, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 26, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 26, 2025 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 23, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 21, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 21, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 21, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 21, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 16, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 16, 2024 TROA
REFUSAL PROCESSED BY IB
Aug 17, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 30, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 30, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 3, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jul 2, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 1, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 18, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 12, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 4, 2024 REPR